




CYBERDYNE



**Consolidated Financial Result Briefing
for the nine months ended December 31, 2024**

CYBERDYNE Inc. (Ticker Code: 7779)

February 13, 2025

Consolidated nine months result summary (IFRS)

(Unit: Millions of yen)	2023/3Q	2024/3Q	+/-	+/-
Revenue	3,219	3,169	-49	-1.5%
Core operating profit (loss)	-999	-584	+ 415	-
Operating profit (loss)	-1,603	-708	+ 895	-
Profit (loss) before tax	-566	-297	+ 269	-
Profit (loss) attributable to owners of parent	-951	-384	+ 567	-

Revenue

3,169 Million
YoY -49 Million (-1.5%)

- Treatment service (RHG etc.) +106 Million (Business +29, Foreign exchange +77)
- Product Rental (Domestic, APAC) +50 Million (Business +27, Foreign exchange +23)
- Product Rental (EMEA, US) -42 Million (Business -58, Foreign exchange +15)
- New business expansion (German: LeyLine) -163 Million (Business -188, Foreign exchange +25)

Core Operating Profit

- 584 Million
YoY + 415 Million

- Treatment Service (RHG etc.) +257 Million (FY24: -97, FY23: -354)
- Product Rental -95 Million (FY24: 504, FY23: 599)
- New business expansion (three subsidiaries) +40 Million (FY24: -148, FY23: -188)
- Improvement of RD expense and head office expense +213 Million (FY24: -843, FY23: -1,057)

Profit before tax

- 297Million
YoY + 269 Million

- Difference of operating income +895 Million
- Gains / Losses related to CEJ Fund -719 Million (FY24: 71 Million, FY23: 790 Million)
- YoY Financial income/Expense mainly from gain from investment +112 Million (FY24: 356 Million – FY23: 245 Million = +112 Million)
- Decrease in investment profit due to equity method -19 Million

※ Core Operating Profit = Operating profit - gains/losses due to non-recurring factors (Foreign exchange gains/losses, impairments, and other one-time gains/losses)

Consolidated results: Revenue/Operating profit (Margin)



Sales of treatment services mainly RHG (US) continued to increase, and operating losses improved
Group-wide operating income also improved from the previous year

(Unit : Millions of yen)		2023/3Q	2024/3Q	+/-	+/- %
Product rental	Revenue	1,294	1,302	+8	+0.6%
	Operating profit (Margin %)	597 (46%)	525 (40%)	-72 (-6pt)	-12.1%
Treatment Service	Revenue	1,239	1,345	+106	+8.5%
	Operating profit (Margin %)	-351 (-28%)	-101 (-7%)	+250 (+21pt)	-
New Business Expansion	Revenue	685	522	-163	-23.8%
	Operating profit (Margin %)	-185 (-27%)	-155 (-30%)	+30 (-3pt)	-
RD expenses and head office expenses	Adjusted amount	-1,664	-978	-686	-
Consolidated total (IFRS)	Revenue	3,219	3,169	-49	-1.5%
	Operating profit (Margin %)	-1,603 (-50%)	-708 (-22%)	+895 (+28pt)	-

- Product rental : Revenue from rental of the Group's products (includes revenue from sales)
- Treatment service : Revenue from treatment services provided through the Group's facilities (including service fees in Robocare Centers)
- New business expansion : Revenue from the Group's new business (e.g. subsidiary in Mobility and Sleeping App)

* Amount of operating profit or loss, which is revenue minus operating expenses, for each business
* Adjusted amount included R&D expenses, head office administrative expenses, other income and expenses, etc.

Revenue by business types & geographical region (Matrix)

RHG (US) treatment service continues to grow steadily

Declining trend in LeyLine (Germany), ASO (Japan) new business expansion

(Unit : Millions of yen) Top : 2024 3Q YTD (Bottom : 2023 3Q YTD)	Japan	EMEA	APAC	AMER	Total	YoY
Product rental	684 (676)	201 (226)	388 (346)	28 (46)	1,302 (1,294)	+8 (+1%)
Treatment Service	96 (107)	44 (40)	-	1,205 (1,091)	1,345 (1,239)	+106 (+9%)
New business Expansion	186 (281)	337 (404)	-	-	522 (685)	-163 (-24%)
Total	966 (1,065)	582 (670)	388 (346)	1,233 (1,137)	3,169 (3,219)	-49 (-2%)
YoY	-99 (-9%)	-88 (-13%)	+42 (+12%)	+96 (+8%)		
	Domestic	Foreign				
Revenue to sales ratio	30%	70%			100%	

AMER : North, Central and South America

EMEA : Europe, the Middle East and Africa

APAC : Asia-Pacific *Excluding Japan

Revenue from rental and sales (by product)

Steadily increase of sales of HAL for Medical Use Lower Limb Type towards new facility in Japan
 Increased revenue outside Japan due to installing HAL Lower Limb type, HAL Single Joint Type, etc. to Social Security Organization, Malaysia.

(Unit : Millions of yen) Top : 2024 3Q YTD (Bottom : 2023 3Q YTD)	Type of product	Japan	Outside Japan	Total
Cybernetics Treatment (Functional improvement and regeneration)	Medical HAL Lower Limb Type	278 (247)	410 (397)	687 (644)
	Non-medical HAL lower Limb Type	118 (122)	-	118 (122)
	HAL Single Joint Type	65 (68)	87 (77)	151 (144)
Well-being and care	HAL Lumbar Type	78 (86)	66 (74)	145 (160)
Labor Support	HAL Lumbar Type	29 (32)	-	29 (32)
	Mobile robot (CL02 etc.)	54 (83)	-	54 (83)
Other (Acoustic X, Other products)		63 (39)	55 (70)	118 (110)
Total		684 (676)	618 (618)	1,302 (1,294)

This presentation contains forward-looking statements concerning CYBERDYNE, Inc. and its Group's future plans, strategies and performance. Forward-looking statements contained in this presentation are based on information currently available and on certain assumption redeemed rational at the time of creation of this presentation. As such, due to various risks and uncertainties, the statements and assumption does not guarantee future performance, may be considered differently from alternative perspectives and may differ from the actual result.

Further, this presentation contains statements and information regarding corporate entities other than those belonging to the CYBERDYNE group, which have been compiled from various publicly- available sources. CYBERDYNE does not verify nor guarantees accuracy and appropriateness of those information.



CYBERDYNE